Cyanide Bridged Platinum‐Iron Complexes as Cisplatin Prodrug Systems: Design and Computational Study

다국어 초록 (Multilingual Abstract)

The potential role of cyanide‐bridged platinum‐iron complexes as an anti‐cancer Pt(IV) prodrug is studied. We present design principles of a dual‐function prodrug that can upon reduction dissociate and release concurrently six cisplatin units and a ferricyanide anion per prodrug unit. The prodrug molecule is a unique complex of hepta metal centers consisting of a ferricyanide core with six Pt(IV) centers each bonded to the Fe(III) core through a cyano ligand. The functionality of the prodrug is addressed through density functional theory (DFT) calculations.
Design principles: Reduction of a novel prodrug releases six cisplatin and ferricyanide for targeted and effective cell apoptosis based on a triggered change in the ligand field of the Pt centers. The functionality of the prodrug is addressed through density functional theory (DFT) calculations.